ICYMI, some of this week’s featured content includes a new podcast episode, and articles about a new black box warning for certain JAK inhibitors, guselkumab vs secukinumab, updates in lasers and light devices, plus more.
This week’s edition of The Mainstream Patient features stories about albinism, salt water for acne, curl gatekeeping, dry scalp, exercising with psoriatic arthritis, plus more.
Holistic options for disease management show improvement in mild psoriasis.
In this month's Cosmetic Conundrums column, Dermatology Times® Chief Medical Editor Zoe Diana Draelos, MD, explores the world of hair, including ammonia-free hair dyes, how conditioner can prevent hair breakage, hair oiling, and more.
The app helps dermatologists and aesthetic physicians promote their practices, gain new clients, and share information.
More options are available to address alopecia, but not all are backed by equally solid science. Strategies for choosing and using new treatments and procedures for full-cycle hair loss management were highlighted at the Music City Symposium for Cosmetic Advances & Laser Education 16th Annual Meeting.
Regeneron Pharmaceuticals, Inc. and Sanofi announced safety and efficacy results from the LIBERTY AD trial investigating dupilumab in pediatric patients ages 6 months to 5 years with atopic dermatitis.
In this month's Legal Eagle column, David J. Goldberg, MD, JD, explores selling your practice to a private equity interest and the challenges that can follow, including staff shortages and longer patient wait times.
COVID-19’s lingering impact brings new considerations for treatment regimens for pediatric patients with psoriasis.
Whitney Linsenmeyer, PhD, RD, LD, provides 3 dietary considerations for patients with psoriasis.
DefenAge unveils the first-ever body cream containing defensins.
Pfizer’s JADE DARE phase 3 trial met its coprimary and key secondary efficacy endpoints.
Theresa Vavra, PharmD, BCPS, provides studies for some of the most commonly used supplements by patients with psoriasis.
Some systemic medications may have increased risk for patients during the COVID-19 era, according to a recent Pediatric Dermatology Research Alliance (PeDRA) statement.
The FDA is now requiring black box warning for certain JAK inhibitors used to treat arthritis. This news comes amid delay in FDA approval for multiple JAK inhibitors for the treatment of inflammatory skin conditions.
Mark Lebwohl, MD, takes a deep dive in the recent delay in approval for multiple JAK inhibitor drugs for treatment of inflammatory skin conditions such as psoriasis and atopic dermatitis. He also discusses the impact of the delay, as well as the benefits of JAK inhibitors for inflammatory skin diseases, and an outlook for the future of this drug class.
Innovations include underserved populations, acne, and advanced applications.
According to a study in Annals of Dermatology and Venerology, pediatric patients with psoriasis in France frequently missed dermatologic consultations.
A study published in the Journal of Dermatological Treatment shows guselkumab may be more effective in heavier patients with moderate to severe plaque psoriasis vs secukinumab.
Omeza announced yesterday that the FDA has given 510(k) clearance for the Omeza Collagen Matrix for chronic wound care.